PTGXProtagonist TherapeuticsPTGX info
$46.15info3.08%24h
Global rank4312
Market cap$2.66B
Change 7d11.18%
YTD Performance101.09%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Protagonist Therapeutics (PTGX) Stock Overview

    Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

    PTGX Stock Information

    Symbol
    PTGX
    Address
    7707 Gateway BoulevardNewark, CA 94560-1160United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.protagonist-inc.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    510 474 0170

    Protagonist Therapeutics (PTGX) Price Chart

    -
    Value:-

    Protagonist Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $46.15
    N/A
    Market Cap
    $2.66B
    N/A
    Shares Outstanding
    57.68M
    N/A
    Employees
    111.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org